Healthcare Equipment and Supplies
Company Overview of Second Sight Medical Products, Inc.
Second Sight Medical Products, Inc., a medical device company, develops, manufactures, and markets implantable visual prosthetics for blind people enabling them to achieve independence. The company develops The Argus II Retinal Prosthesis System, a bionic eye or retinal implant that restores functional vision for people suffering from blindness. It serves patients and families, and healthcare professionals. The company was founded in 1998 and is headquartered in Sylmar, California with an additional office in Lausanne, Switzerland.
12744 San Fernando Road
Sylmar, CA 91342
Founded in 1998
Key Executives for Second Sight Medical Products, Inc.
Chief Executive Officer and President
Co-Founder and Chairman of The Board
Vice President of Clinical and Regulatory Affairs
Compensation as of Fiscal Year 2013.
Second Sight Medical Products, Inc. Key Developments
Second Sight Medical Products, Inc. Presents at 15th Annual SoCalBio Investor & Partnership Conference, Nov-06-2013 02:45 PM
Nov 3 13
Second Sight Medical Products, Inc. Presents at 15th Annual SoCalBio Investor & Partnership Conference, Nov-06-2013 02:45 PM. Venue: Omni Hotel, 251 South Olive Street, Los Angeles, CA 90012, United States. Speakers: Arup Roy, PhD, Director of Systems R&D Group.
Second Sight Medical Products's Argus(R) II Retinal Implant Now Available Also in the Netherlands
Jul 4 13
Second Sight Medical Products, Inc. announced that Argus II Bionic Eye is now also available in the Netherlands. Many patients suffering from Retinitis Pigmentosa have now the possibility to regain some functional vision with this treatment. In the Argus II Retinal Prosthesis System a mini camera mounted on sunglasses captures the scene. The images are first processed by a video processing unit; this data is then transmitted wirelessly to the implant that stimulates the remaining healthy cells of the retina, inducing pattern of lights that the brain interprets as shapes and movements. This technique allows blind people who suffer from the hereditary condition to distinguish light and contours again. Clinical results have demonstrated that Argus II is reliable over the long term and provides benefit to implanted patients followed up to 5 years. In daily life activities, profoundly blind Argus II users improved dramatically in their ability to conduct visual tasks and complement to other assistive means used by the blind. It may also enable other life style tasks generally considered impossible for the blind (for example reading). For all users, it means being connected to the visual world again, with all its associated advantages in terms of social interactions, and independence. The treatment has been commercially available till now in many hospitals worldwide, located in Germany, Italy, England, France, Switzerland, Saudi Arabia and the USA.
Second Sight Medical Products, Inc. Receives FDA Approval for its Argus(R) II Retinal Prosthesis System
Feb 14 13
Second Sight Medical Products, Inc. announced that its Argus(R) II Retinal Prosthesis System has received U.S. market approval from the Food and Drug Administration (FDA) to treat individuals with late stage Retinitis Pigmentosa (RP). Argus II is intended to provide electrical stimulation of the retina to induce visual perception in blind individuals with retinitis pigmentosa and has the capacity to offer life-changing visual capabilities to those currently unable to see anything except, at best, extremely bright lights. Although the resulting vision is not the same as when these patients had normal vision, investigators involved in the clinical trial of the Argus II are eager about the approval. With approval from the FDA, the Argus II is slated to be available later this year in clinical centers across the country. Second Sight will be actively adding sites to make the therapy more readily available and encourages interested facilities and patients to contact them.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 23, 2013
January 28, 2013